CAS · 1092939-17-7
Product Overview
Ruxolitinib Phosphate is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Off white or white powder |
|---|---|
| Purity (HPLC) | 99% min. |
| Identification by NMR | Conforms to the reference spectrum |
| Identification by IR | The IR absorption of the sample must be concordant with Test Standard |
| Residue on ignition | 0.2% max. |
| Water by KF | 1% max. |
Applications
Ruxolitinib Phosphate is primarily used in the pharmaceutical industry as a potent Janus kinase (JAK) inhibitor. It is applied in the treatment of myeloproliferative disorders such as myelofibrosis and polycythemia vera, where dysregulated JAK-STAT signaling drives abnormal cell proliferation. The compound is also investigated in research for other inflammatory and autoimmune conditions, including graft-versus-host disease and certain dermatological disorders, due to its immunomodulatory properties. In drug development, Ruxolitinib Phosphate is utilized as a model JAK inhibitor for studying kinase signaling pathways, optimizing pharmacokinetics, and developing new formulations for oral or topical delivery.
Benefits
Ruxolitinib Phosphate offers several advantages in therapeutic and research applications. Its selective inhibition of JAK1 and JAK2 kinases provides targeted modulation of cytokine signaling pathways, reducing abnormal cell proliferation and inflammation with controlled specificity. The phosphate salt form enhances water solubility and bioavailability, facilitating formulation into oral or injectable preparations. The compound has demonstrated efficacy in clinical studies for improving symptoms, reducing spleen size, and enhancing quality of life in patients with myeloproliferative disorders. Its well-characterized pharmacological profile and reproducibility support both clinical and preclinical research in kinase inhibition and immune modulation.
Conclusion
Ruxolitinib Phosphate is a selective JAK inhibitor with applications in the treatment of myeloproliferative and autoimmune disorders, as well as in research on kinase signaling. Its targeted activity, solubility, and clinical efficacy make it valuable in both therapeutic and drug development contexts. Overall, Ruxolitinib Phosphate supports precise modulation of JAK-STAT pathways, improving patient outcomes and advancing pharmacological research.
Previous
(+/-)-Verapamil Hydrochloride丨CAS 152-11-4
Next